TfR1-Targeted Bicyclic Peptide-Oligonucleotide Conjugates for Improved Potency and Enhanced Muscle Delivery
Antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) are uniquely suited to address single-gene diseases affecting skeletal and cardiac muscles. While distributed broadly, they are more likely to accumulate in the liver and kidneys than muscles, thus limiting their treatment applicability. Additionally, the anticipated ...
Chance, Choice, and Conviction: A Career in Oligonucleotide Therapeutics
Date: June 4, 2026 Time: 11am-12pm EDT / 5-6pm CEST Register Here Title: Chance, Choice, and Conviction: A Career in Oligonucleotide Therapeutics Description: An insight into how a combination of (taking) chance, role models, mentors, becoming better at making informed decisions, and ...
A Message from Dr. Rebecca Miles
As we begin 2026, I am honored to welcome you to a new year and a new chapter for the Oligonucleotide Therapeutics Society. The start of the year is a natural moment for reflection on how far our field has come, and on the ...
Selection of DNA Aptamers to Inhibit TDP-43 Aggregation in ALS
Date: May 7, 2026 Time: 11-12pm EDT / 5-6pm CEST Title: Selection of DNA Aptamers to Inhibit TDP-43 Aggregation in ALS Description: Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease characterized by the loss of motor neurons. With an unknown ...
Trainee Spotlight Series: 2025 Oligo Meeting Poster Winners 5
Date: April 16, 2026Time: 11-12pm EDT / 5-6pm CEST Title: Development of an N=1 Therapeutic Antisense Oligonucleotide for a unique UNC13A variant Description: Rare disorders collectively affect 3 to 10% of the population, but treatment options are scarce. Recently, genetic variants ...
OTS Member Highlight – Dr. Rebecca Miles
The incoming OTS President, Dr. Rebecca Miles, has always been curious about the way things work, and in high school, a human anatomy and physiology class sparked her passion for researching human diseases. As the first person in her family to pursue higher education, ...
Extended Nucleic Acid Therapeutics: Unlocking potential through tiny methylene chemical modifications
Date: April 2, 2026Time: 11-12pm EDT / 5-6pm CEST Title: Extended Nucleic Acid Therapeutics: Unlocking potential through tiny methylene chemical modifications Description: Modulation of the backbone structures of oligonucleotides has a profound impact on the pharmacokinetics and pharmacodynamics of RNA medicines. ...
Small Nuclear RNAs (snRNAs) Enhance RNA Base Editing
Gene editing technologies are transforming molecular medicine, offering unprecedented potential to treat — and even cure — a range of genetic disorders. However, as tools like CRISPR enter clinical settings, concerns about its safety, specificity, and long-term side effects, such as off-target edits or ...
Advancing Prime Editing–Based Genome Editing Technologies for Therapeutic Applications
Date: March 26, 2026 Time: 12-1pm EDT / 5-6pm CET Title: Advancing Prime Editing–Based Genome Editing Technologies for Therapeutic Applications Description: In this webinar, I will discuss recent advances in prime editing–based genome engineering, including split prime editing, template-jumping prime editing, ...
Meet the 2026 Trainee Reps
Date: March 19, 2026 Time: 12-1pm EDT / 5-6pm CET Title: A Trainee's Perspective: Advocacy & Research in ALS Description: In this talk, Daniel will introduce himself as one of the two newest trainee representatives on the OTS Board of Directors ...
